Ludwig Announces Substantial Corporate Initiatives

Rhea-AI Summary

Ludwig Enterprises, Inc. (OTC PINK:LUDG) has announced significant corporate initiatives as it prepares to launch Revealia™, its innovative cancer screening test, in 2024. The company plans to change its name to Revealia™, Inc. and apply for OTCQB listing, with aspirations for higher listings like NASDAQ or CBOE in the future. Revealia™ is positioned as the world's most convenient cancer screening test, utilizing a simple mail-order noninvasive cheek swab.

The company has collected over 3000 mRNA samples from multiple medical clinics across the US and employs proprietary machine learning AI technology for continuous statistical updates. CEO Marvin S. Hausman, MD, states that Ludwig has uncovered potentially game-changing mRNA-based genetic signals associated with cancer presence.

Positive

• Planned launch of Revealia™ cancer screening test in 2024
• Intention to uplist to OTCQB, with future plans for NASDAQ or CBOE listing
• Collection of over 3000 mRNA samples for product development
• Use of proprietary machine learning AI technology for data analysis
• Potential discovery of significant mRNA-based genetic signals for cancer detection

Negative

• Current trading on OTC Pink market, which is less regulated than higher exchanges
• Pending regulatory approvals for corporate name change and new ticker symbol
• Entering a competitive market against established players like Exact Sciences

Revealia™, the world's most convenient cancer screening test, to launch in 2024

SPARKS, NV / ACCESSWIRE / August 14, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG), a USA-based biotechnology company, is pleased to announce its corporate vision for the next 120 days. Ludwig has embarked on a plan to reshape the Company as it nears its launch of Revealia™.

A key initiative is the change of corporate name to "Revealia™, Inc." Following regulatory approvals, the new company name and a new ticker to match the name would be in place. Revealia™ is also the name of the company's cancer screening product.

The Company intends to apply with OTCMarkets to begin trading on the OTCQB, a first step in its longer-range plan of seeking a higher listing, such as NASDAQ or CBOE.

These corporate initiatives are a direct result of the company being in a position to launch its much-anticipated cancer screening kit, Revealia™. This kit will be among the most sophisticated on the market, aiming to compete against competitors in the highly profitable genetic cancer screening market, such as Exact Sciences, which launched Cologuard in 2014, the first stool DNA test for colorectal cancer. Revealia™, the world's most convenient cancer screening test, is planned to hit the direct-to-consumer market in 2024. A simple mail-order noninvasive cheek swab can help save lives. "Ludwig has uncovered potentially game-changing mRNA-based genetic signals associated with the presence of cancer," stated Marvin S. Hausman, MD, CEO. The Company, which has collected over 3000 samples to date, continues to collect mRNA samples from over 40 multipurpose medical clinics throughout the United States. Our proprietary machine learning AI technology allows continuous statistical updates as additional patient data is received.

About Ludwig Enterprises, Inc.

Ludwig Enterprises, Inc., a biotech and healthcare holding company, is a global leader in mRNA genomics and machine learning AI technology. Our mission is to identify, monitor, and create solutions to prevent chronic inflammation, the causative agent of illnesses™ such as cancer and heart disease, which are responsible for more than 50% of deaths worldwide.

For more information please visit: http://www.ludwigent.com.

SAFE HARBOR

Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.

CONTACT:

Ludwig Enterprises, Inc.
Marvin S. Hausman MD, CEO
marvin@ludwigent.com
www.ludwigent.com

SOURCE: Ludwig Enterprises Inc.

View the original press release on accesswire.com

FAQ

When is Ludwig Enterprises (LUDG) planning to launch its Revealia™ cancer screening test?

Ludwig Enterprises (LUDG) plans to launch Revealia™, described as the world's most convenient cancer screening test, in 2024 for the direct-to-consumer market.

What corporate changes is Ludwig Enterprises (LUDG) planning to implement?

Ludwig Enterprises (LUDG) is planning to change its corporate name to 'Revealia™, Inc.', apply for OTCQB listing, and eventually seek higher listings such as NASDAQ or CBOE.

How does Ludwig Enterprises' (LUDG) Revealia™ cancer screening test work?

Revealia™ by Ludwig Enterprises (LUDG) is a noninvasive cancer screening test that uses a simple mail-order cheek swab to collect mRNA samples for analysis.

How many mRNA samples has Ludwig Enterprises (LUDG) collected for its cancer screening research?

Ludwig Enterprises (LUDG) has collected over 3000 mRNA samples to date from more than 40 multipurpose medical clinics throughout the United States.